Clive Page

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6873213/publications.pdf

Version: 2024-02-01

133	5,448	94433	91884
papers	citations	37 h-index	69 g-index

134	134	134	6552
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Novel pharmacological therapies for the treatment of bronchial asthma. Minerva Medica, 2022, 113, .	0.9	7
2	Inhaled nebulised unfractionated heparin for the treatment of hospitalised patients with COVIDâ€19: A multicentre case series of 98 patients. British Journal of Clinical Pharmacology, 2022, 88, 2802-2813.	2.4	17
3	Can nebulised HepArin Reduce morTality and time to Extubation in patients with COVIDâ€19 Requiring invasive ventilation Metaâ€Trial (CHARTERâ€MT): Protocol and statistical analysis plan for an investigatorâ€initiated international metaâ€trial of prospective randomised clinical studies. British Journal of Clinical Pharmacology, 2022, 88, 3272-3287.	2.4	9
4	Prescribing the right therapy for the treatment of chronic cough: a critical focus on current and investigational options. Expert Opinion on Pharmacotherapy, 2022, , 1-4.	1.8	0
5	Dual bronchodilation for the treatment of COPD: From bench to bedside. British Journal of Clinical Pharmacology, 2022, 88, 3657-3673.	2.4	10
6	Prospects for COPD treatment. Current Opinion in Pharmacology, 2021, 56, 74-84.	3.5	45
7	Unfractionated heparin inhibits live wild type SARSâ€CoVâ€2 cell infectivity at therapeutically relevant concentrations. British Journal of Pharmacology, 2021, 178, 626-635.	5.4	73
8	Platelets Independently Recruit into Asthmatic Lungs and Models of Allergic Inflammation via CCR3. American Journal of Respiratory Cell and Molecular Biology, 2021, 64, 557-568.	2.9	18
9	A peptide derived from chaperonin 60.1, IRL201104, inhibits LPS-induced acute lung inflammation. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2021, 321, L803-L813.	2.9	3
10	The anti-inflammatory effects of cannabidiol and cannabigerol alone, and in combination. Pulmonary Pharmacology and Therapeutics, 2021, 69, 102047.	2.6	24
11	Multi-walled carbon nanotubes induce airway hyperresponsiveness in human bronchi by stimulating sensory C-fibers and increasing the release of neuronal acetylcholine. Expert Review of Respiratory Medicine, 2021, 15, 1473-1481.	2.5	5
12	INHALEd nebulised unfractionated HEParin for the treatment of hospitalised patients with COVIDâ€19 (INHALEâ€HEP): Protocol and statistical analysis plan for an investigatorâ€initiated international metatrial of randomised studies. British Journal of Clinical Pharmacology, 2021, 87, 3075-3091.	2.4	19
13	Nonantimicrobial Actions of Macrolides: Overview and Perspectives for Future Development. Pharmacological Reviews, 2021, 73, 1404-1433.	16.0	40
14	Red Blood Cells Elicit Platelet-Dependent Neutrophil Recruitment Into Lung Airspaces. Shock, 2021, 56, 278-286.	2.1	4
15	Beclomethasone dipropionate, formoterol fumarate and glycopyrronium bromide: Synergy of triple combination therapy on human airway smooth muscle ex vivo. British Journal of Pharmacology, 2020, 177, 1150-1163.	5.4	47
16	Modulation of allergic inflammation in the lung by a peptide derived from Mycobacteria tuberculosis chaperonin 60.1. Clinical and Experimental Allergy, 2020, 50, 508-519.	2.9	7
17	Sex differences in the influence of obesity on a murine model of allergic lung inflammation. Clinical and Experimental Allergy, 2020, 50, 256-266.	2.9	15
18	Multifaceted Beneficial Effects of Erdosteine: More than a Mucolytic Agent. Drugs, 2020, 80, 1799-1809.	10.9	21

#	Article	IF	Citations
19	An in vitro bioassay for evaluating the effect of inhaled bronchodilators on airway smooth muscle. Pulmonary Pharmacology and Therapeutics, 2020, 63, 101943.	2.6	0
20	Update on animal models for COVIDâ€19 research. British Journal of Pharmacology, 2020, 177, 5679-5681.	5.4	8
21	Nebulised heparin as a treatment for COVID-19: scientific rationale and a call for randomised evidence. Critical Care, 2020, 24, 454.	5.8	81
22	Heparin and non-anticoagulant heparin attenuate histone-induced inflammatory responses in whole blood. PLoS ONE, 2020, 15, e0233644.	2.5	37
23	Animal models of mechanisms of <scp>SARSâ€CoVâ€2</scp> infection and <scp>COVIDâ€19</scp> pathology. British Journal of Pharmacology, 2020, 177, 4851-4865.	5.4	158
24	Title is missing!. , 2020, 15, e0233644.		0
25	Title is missing!. , 2020, 15, e0233644.		0
26	Title is missing!. , 2020, 15, e0233644.		0
27	Title is missing!. , 2020, 15, e0233644.		0
28	Comparison of Oral, Intranasal and Aerosol Administration of Amiodarone in Rats as a Model of Pulmonary Phospholipidosis. Pharmaceutics, 2019, 11, 345.	4.5	11
29	Long-term observational study on the impact of GLP-1R agonists on lung function in diabetic patients. Respiratory Medicine, 2019, 154, 86-92.	2.9	35
30	Thiol-Based Drugs in Pulmonary Medicine: Much More than Mucolytics. Trends in Pharmacological Sciences, 2019, 40, 452-463.	8.7	42
31	Efficacy and safety profile of mucolytic/antioxidant agents in chronic obstructive pulmonary disease: a comparative analysis across erdosteine, carbocysteine, and N-acetylcysteine. Respiratory Research, 2019, 20, 104.	3.6	45
32	Antitussive therapy: A role for levodropropizine. Pulmonary Pharmacology and Therapeutics, 2019, 56, 79-85.	2.6	10
33	Pharmacological characterization of the interaction between tiotropium bromide and olodaterol on human bronchi and small airways. Pulmonary Pharmacology and Therapeutics, 2019, 56, 39-50.	2.6	21
34	LPS-induced Lung Platelet Recruitment Occurs Independently from Neutrophils, PSGL-1, and P-Selectin. American Journal of Respiratory Cell and Molecular Biology, 2019, 61, 232-243.	2.9	38
35	Effect of Erdosteine on COPD Exacerbations in COPD Patients with Moderate Airflow Limitation . International Journal of COPD, 2019, Volume 14, 2733-2744.	2.3	23
36	Perspectives of Pharmacology over the Past 100 Years. Handbook of Experimental Pharmacology, 2019, 260, 3-16.	1.8	2

#	Article	IF	Citations
37	Effect of lipopolysaccharide on the responsiveness of equine bronchial tissue. Pulmonary Pharmacology and Therapeutics, 2018, 49, 88-94.	2.6	7
38	Platelets Play a Central Role in Sensitization to Allergen. American Journal of Respiratory Cell and Molecular Biology, 2018, 59, 96-103.	2.9	14
39	Realising the potential of various inhaled airway challenge agents through improved delivery to the lungs. Pulmonary Pharmacology and Therapeutics, 2018, 49, 27-35.	2.6	3
40	Long-Acting Î²2-Agonists in Asthma: Enantioselective Safety Studies are Needed. Drug Safety, 2018, 41, 441-449.	3.2	11
41	Impact of doxofylline in COPD: A pairwise meta-analysis. Pulmonary Pharmacology and Therapeutics, 2018, 51, 1-9.	2.6	17
42	Diverse signalling of the platelet P2Y1 receptor leads to a dichotomy in platelet function. European Journal of Pharmacology, 2018, 827, 58-70.	3.5	19
43	Platelet Depletion Impairs Host Defense to Pulmonary Infection with Pseudomonas aeruginosa in Mice. American Journal of Respiratory Cell and Molecular Biology, 2018, 58, 331-340.	2.9	55
44	Steroid sparing effects of doxofylline. Pulmonary Pharmacology and Therapeutics, 2018, 48, 1-4.	2.6	18
45	Inhaled nebulised unfractionated heparin improves lung function in moderate to very severe COPD: A pilot study. Pulmonary Pharmacology and Therapeutics, 2018, 48, 88-96.	2.6	39
46	Impact of erdosteine on chronic bronchitis and COPD: A meta-analysis. Pulmonary Pharmacology and Therapeutics, 2018, 48, 185-194.	2.6	20
47	Ensifentrine (RPL554): an inhaled â€˜bifunctionalâ€™ dual PDE3/4 inhibitor for the treatment of asthma and chronic obstructive pulmonary disease. Pharmaceutical Patent Analyst, 2018, 7, 249-257.	1.1	13
48	A dichotomy in platelet activation: Evidence of different functional platelet responses to inflammatory versus haemostatic stimuli. Thrombosis Research, 2018, 172, 110-118.	1.7	18
49	Gustav Born: pioneer in imaging platelet and leukocyte biology. Platelets, 2018, 29, 766-770.	2.3	0
50	Pharmacokinetic considerations concerning the use of bronchodilators in the treatment of chronic obstructive pulmonary disease. Expert Opinion on Drug Metabolism and Toxicology, 2018, 14, 1101-1111.	3.3	10
51	An inhaled â€œbifunctionalâ€•dual PDE3/4 inhibitor provides additional short-term improvements in lung function compared to existing classes of bronchodilator: implications for future treatment of COPD. European Respiratory Journal, 2018, 52, 1801675.	6.7	9
52	Î²2-Adrenoceptor signalling bias in asthma and COPD and the potential impact on the comorbidities associated with these diseases. Current Opinion in Pharmacology, 2018, 40, 142-146.	3.5	24
53	Inhaled PDE3/4 inhibitors as novel “bifunctional” drugs for the treatment of asthma and chronic obstructive pulmonary disease (COPD). Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, SY64-3.	0.0	0
54	Management of Chronic Obstructive Pulmonary Disease in Patients with Cardiovascular Diseases. Drugs, 2017, 77, 721-732.	10.9	29

#	Article	IF	Citations
55	Effect of erdosteine on the rate and duration of COPD exacerbations: the RESTORE study. European Respiratory Journal, 2017, 50, 1700711.	6.7	68
56	Targeting Mechanisms Linking COPD to Type 2 Diabetes Mellitus. Trends in Pharmacological Sciences, 2017, 38, 940-951.	8.7	46
57	Predicting the Fine Particle Fraction of Dry Powder Inhalers Using Artificial Neural Networks. Journal of Pharmaceutical Sciences, 2017, 106, 313-321.	3.3	20
58	Doxofylline is not just another theophylline!. International Journal of COPD, 2017, Volume 12, 3487-3493.	2.3	39
59	Plateletâ€“Eosinophil Interactions As a Potential Therapeutic Target in Allergic Inflammation and Asthma. Frontiers in Medicine, 2017, 4, 129.	2.6	36
60	The effect of N -acetylcysteine on biofilms: Implications for the treatment of respiratory tract infections. Respiratory Medicine, 2016, 117, 190-197.	2.9	136
61	Using Salt Counterions to Modify Î²₂-Agonist Behavior in Vivo. Molecular Pharmaceutics, 2016, 13, 3439-3448.	4.6	6
62	A Non-Anticoagulant Fraction of Heparin Inhibits Leukocyte Diapedesis into the Lung by an Effect on Platelets. American Journal of Respiratory Cell and Molecular Biology, 2016, 55, 554-563.	2.9	20
63	Base-modified UDP-sugars reduce cell surface levels of P-selectin glycoprotein 1 (PSGL-1) on IL-1Î²-stimulated human monocytes. Glycobiology, 2016, 26, 1059-1071.	2.5	13
64	Therapeutic Monoclonal Antibodies for the Treatment of Chronic Obstructive Pulmonary Disease. Drugs, 2016, 76, 1257-1270.	10.9	36
65	Antitussive effect of carcainium chloride in patients with chronic cough and idiopathic interstitial pneumonias: A pilot study. Pulmonary Pharmacology and Therapeutics, 2016, 40, 91-94.	2.6	11
66	Pathogenesis of COPD and Asthma. Handbook of Experimental Pharmacology, 2016, 237, 1-21.	1.8	23
67	Brain natriuretic peptide: Much more than a biomarker. International Journal of Cardiology, 2016, 221, 1031-1038.	1.7	51
68	Bifunctional Drugs for the Treatment of Respiratory Diseases. Handbook of Experimental Pharmacology, 2016, 237, 197-212.	1.8	20
69	Biochemical and functional characterization of glycosaminoglycans released from degranulating rat peritoneal mast cells: Insights into the physiological role of endogenous heparin. Pulmonary Pharmacology and Therapeutics, 2016, 41, 96-102.	2.6	5
70	Structural characterization and anti-inflammatory activity of two novel polysaccharides from the sea squirt, Ascidiella aspersa. Pulmonary Pharmacology and Therapeutics, 2016, 40, 69-79.	2.6	10
71	Lung inflammation does not affect the clearance kinetics of lipid nanocapsules following pulmonary administration. Journal of Controlled Release, 2016, 235, 24-33.	9.9	15
72	Pharmacology of Heparin and Related Drugs. Pharmacological Reviews, 2016, 68, 76-141.	16.0	250

#	Article	IF	Citations
73	Ozone-Induced Hypertussive Responses in Rabbits and Guinea Pigs. Journal of Pharmacology and Experimental Therapeutics, 2016, 357, 73-83.	2.5	15
74	P-Rex and Vav Rac-GEFs in platelets control leukocyte recruitment to sites of inflammation. Blood, 2015, 125, 1146-1158.	1.4	76
75	Interaction of Formulation and Device Factors Determine the In Vitro Performance of Salbutamol Sulphate Dry Powders for Inhalation. Journal of Pharmaceutical Sciences, 2015, 104, 3861-3869.	3.3	7
76	The Role of Heparanase in Pulmonary Cell Recruitment in Response to an Allergic but Not Non-Allergic Stimulus. PLoS ONE, 2015, 10, e0127032.	2.5	35
77	The Effect of Phytocannabinoids on Airway Hyper-Responsiveness, Airway Inflammation, and Cough. Journal of Pharmacology and Experimental Therapeutics, 2015, 353, 169-180.	2.5	28
78	Pharmacological characterization of the interaction between the dual phosphodiesterase (PDE) 3/4 inhibitor RPL554 and glycopyrronium on human isolated bronchi and small airways. Pulmonary Pharmacology and Therapeutics, 2015, 32, 15-23.	2.6	46
79	Role of platelets in allergic airway inflammation. Journal of Allergy and Clinical Immunology, 2015, 135, 1416-1423.	2.9	66
80	RhoA signaling through platelet P2Y1 receptor controls leukocyte recruitment in allergic mice. Journal of Allergy and Clinical Immunology, 2015, 135, 528-538.e4.	2.9	60
81	Adenosine monophosphate is elevated in the bronchoalveolar lavage fluid of mice with acute respiratory toxicity induced by nanoparticles with high surface hydrophobicity. Nanotoxicology, 2015, 9, 106-115.	3.0	16
82	Editorial overview: Respiratory: Cough: a burning issue. Current Opinion in Pharmacology, 2015, 22, iv.	3.5	0
83	Contribution of sensory nerves to LPS-induced hyperresponsiveness of human isolated bronchi. Life Sciences, 2015, 131, 44-50.	4.3	20
84	Influence ofN-acetylcysteine on chronic bronchitis or COPD exacerbations: a meta-analysis. European Respiratory Review, 2015, 24, 451-461.	7.1	140
85	Phosphodiesterase Inhibitors for the Treatment of Asthma and Chronic Obstructive Pulmonary Disease. International Archives of Allergy and Immunology, 2014, 165, 152-164.	2.1	57
86	Fucosylated Chondroitin Sulfates from the Body Wall of the Sea Cucumber Holothuria forskali. Journal of Biological Chemistry, 2014, 289, 28284-28298.	3.4	88
87	Pharmacological characterization of the interaction between aclidinium bromide and formoterol fumarate on human isolated bronchi. European Journal of Pharmacology, 2014, 745, 135-143.	3.5	80
88	Heparanase induces inflammatory cell recruitment in vivo by promoting adhesion to vascular endothelium. American Journal of Physiology - Cell Physiology, 2014, 306, C1184-C1190.	4.6	38
89	Use of indacaterol for the treatment of COPD: a pharmacokinetic evaluation. Expert Opinion on Drug Metabolism and Toxicology, 2014, 10, 129-137.	3.3	15
90	Bifunctional drugs for the treatment of asthma and chronic obstructive pulmonary disease. European Respiratory Journal, 2014, 44, 475-482.	6.7	48

#	Article	IF	Citations
91	Doxofylline, a novofylline inhibits lung inflammation induced by lipopolysacharide in the mouse. Pulmonary Pharmacology and Therapeutics, 2014, 27, 170-178.	2.6	26
92	A combined phase I/IIa study of the safety, bronchodilator and bronchoprotective effects of nebulized RPL554, a dual PDE3/4â€inhibitor, in healthy subjects and asthmatics. Clinical and Translational Allergy, 2013, 3, O13.	3.2	1
93	Long-acting muscarinic receptor antagonists for the treatment of respiratory disease. Pulmonary Pharmacology and Therapeutics, 2013, 26, 307-317.	2.6	65
94	Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials. Lancet Respiratory Medicine,the, 2013, 1, 714-727.	10.7	121
95	Neutrophil and platelet complexes and their relevance to neutrophil recruitment and activation. International Immunopharmacology, 2013, 17, 1176-1184.	3.8	106
96	Heparin and Related Drugs: Beyond Anticoagulant Activity. ISRN Pharmacology, 2013, 2013, 1-13.	1.6	59
97	Sir <scp>D</scp>avid <scp>J</scp>ack: an extraordinary drug discoverer and developer. British Journal of Clinical Pharmacology, 2013, 75, 1213-1218.	2.4	6
98	Selective PDE inhibitors as novel treatments for respiratory diseases. Current Opinion in Pharmacology, 2012, 12, 275-286.	3.5	128
99	Pharmacology and Therapeutics of Bronchodilators. Pharmacological Reviews, 2012, 64, 450-504.	16.0	379
100	Paradoxical pharmacology: turning our pharmacological models upside down. Trends in Pharmacological Sciences, 2011, 32, 197-200.	8.7	17
101	Validating 123I-metaiodobenzylguanidine as a platelet marker for non-invasive imaging in rabbits. Journal of Pharmacological and Toxicological Methods, 2011, 63, 69-78.	0.7	1
102	Circulating platelet-neutrophil complexes are important for subsequent neutrophil activation and migration. Journal of Applied Physiology, 2010, 109, 758-767.	2.5	136
103	Doxofylline: A â€œNovofyllineâ€• Pulmonary Pharmacology and Therapeutics, 2010, 23, 231-234.	2.6	49
104	The role of biomarkers in respiratory disease. Pulmonary Pharmacology and Therapeutics, 2010, 23, 466-467.	2.6	0
105	Novel pharmacological approaches to airway and pulmonary vascular disease. Current Opinion in Pharmacology, 2009, 9, 229-230.	3.5	0
106	The rabbit as a model to study asthma and other lung diseases. Pulmonary Pharmacology and Therapeutics, 2008, 21, 721-730.	2.6	36
107	In-vivo skills and UK competitiveness in biomedical sciences. Lancet, The, 2008, 371, 708-709.	13.7	1
108	Allergen Induces the Migration of Platelets to Lung Tissue in Allergic Asthma. American Journal of Respiratory and Critical Care Medicine, 2008, 177, 604-612.	5.6	147

#	Article	IF	Citations
109	Roflumilast: a phosphodiesterase-4 inhibitor for the treatment of respiratory disease. Expert Opinion on Investigational Drugs, 2006, 15, 1105-1113.	4.1	22
110	Phosphodiesterase inhibitors. British Journal of Pharmacology, 2006, 147, S252-7.	5.4	338
111	Î²₂-Agonists and Bronchial Hyperresponsiveness. Clinical Reviews in Allergy and Immunology, 2006, 31, 143-162.	6.5	14
112	Some structural determinants of the antiproliferative effect of heparin-like molecules on human airway smooth muscle. British Journal of Pharmacology, 2005, 146, 370-377.	5.4	31
113	Platelet P-selectin is required for pulmonary eosinophil and lymphocyte recruitment in a murine model of allergic inflammation. Blood, 2005, 105, 2074-2081.	1.4	190
114	Models used in the development of antitussive drugs. Drug Discovery Today: Disease Models, 2004, 1, 297-302.	1.2	9
115	Mechanisms of acute cough. Pulmonary Pharmacology and Therapeutics, 2004, 17, 389-391.	2.6	5
116	Platelets are necessary for airway wall remodeling in a murine model of chronic allergic inflammation. Blood, 2004, 103, 639-647.	1.4	135
117	Extracellular matrix composition influences the resistance of airway remodelling events towards glucocorticoid treatment. British Journal of Pharmacology, 2003, 138, 1181-1182.	5.4	5
118	Platelets are essential for leukocyte recruitment in allergic inflammation. Journal of Allergy and Clinical Immunology, 2003, 112, 109-118.	2.9	197
119	Pharmacology of a new cyclic nucleotide phosphodiesterase type 4 inhibitor, V11294. Pulmonary Pharmacology and Therapeutics, 2003, 16, 97-104.	2.6	18
120	A new model for the continuous monitoring of polymorphonuclear leukocyte trapping in the pulmonary vasculature of the rabbit. Journal of Pharmacological and Toxicological Methods, 2002, 48, 21-29.	0.7	5
121	Role of glycosaminoglycans in inflammation. Inflammopharmacology, 2001, 9, 165-169.	3.9	15
122	A comparison of allergen and polycation induced cutaneous responses in the rabbit. British Journal of Pharmacology, 2001, 133, 1181-1189.	5.4	8
123	The effects of heparin on the adhesion of human peripheral blood mononuclear cells to human stimulated umbilical vein endothelial cells. British Journal of Pharmacology, 2001, 134, 827-836.	5.4	23
124	The effects of heparin and related molecules upon the adhesion of human polymorphonuclear leucocytes to vascular endothelium in vitro. British Journal of Pharmacology, 2000, 129, 533-540.	5.4	94
125	Effects of dexamethasone on airway hyper-responsiveness to the adenosine A1 receptor agonist cyclo-pentyl adenosine in an allergic rabbit model. British Journal of Pharmacology, 1999, 126, 1513-1521.	5.4	9
126	Regulation of platelet function by catecholamines in the cerebral vasculature of the rabbit. British Journal of Pharmacology, 1999, 127, 1652-1656.	5.4	13

#	Article	IF	Citations
127	Effects of dopamine and selective dopamine agonists upon platelet accumulation in the cerebral and pulmonary vasculature of the rabbit. British Journal of Pharmacology, 1997, 122, 682-686.	5.4	9
128	Effect of a 5â€lipoxygenase inhibitor and leukotriene antagonist (PF 5901) on antigenâ€induced airway responses in neonatally immunized rabbits. British Journal of Pharmacology, 1994, 112, 292-298.	5.4	21
129	Effect of PF 10040 on PAFâ€induced airway responses in neonatally immunized rabbits. British Journal of Pharmacology, 1994, 111, 7-12.	5.4	5
130	Effect of heparin and a lowâ€molecular weight heparinoid on PAFâ€induced airway responses in neonatally immunized rabbits. British Journal of Pharmacology, 1993, 110, 107-112.	5.4	35
131	Effect of a 5â€lipoxygenase inhibitor and leukotriene antagonist (PF 5901) on PAFâ€induced airway responses in neonatally immunized rabbits. British Journal of Pharmacology, 1992, 107, 1108-1115.	5.4	19
132	Effects of bradykinin receptor antagonists on antigenâ€induced respiratory distress, airway hyperresponsiveness and eosinophilia in guineaâ€pigs. British Journal of Pharmacology, 1992, 107, 653-659.	5.4	40
133	The Requirement for Platelets in Allergen-induced Late Asthmatic Airway Obstruction: Eosinophil Infiltration and Heightened Airway Responsiveness in Allergic Rabbits. The American Review of Respiratory Disease, 1990, 142, 587-593.	2.9	89